Arca
Skip to content
Tools
Tools

Troponin, cardiac muscle

Complex in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on TNNC1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 31

    • Levosimendan

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        LevosimendanPhase 3Tenax TherapeuticsSmall moleculePositive modulatorTroponin, cardiac muscle positive modulator9

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary ThromboendarterectomyLevosimendanNot applicableRecruitingMeshalkin Research Institute of Pathology of CirculationNov 4, 2026
        Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility StudyLevosimendanNot applicableRecruitingNiguarda HospitalJun 24, 2026
        Long-Term Open-Label Extension Study of Oral LevosimendanLevosimendanPhase 3Enrolling by invitationTenax Therapeutics, Inc.Feb 27, 2026
        LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2LevosimendanPhase 3Active, not recruitingTenax Therapeutics, Inc.Dec 17, 2025
        Levosimendan in Acute Decompensated Heart FailureLevosimendanPhase 2 / Phase 3Not yet recruitingChittagong Medical CollegeDec 4, 2025
        Shorter Weaning From Invasive Ventilation With LevosimendanLevosimendanPhase 4RecruitingRadboud University Medical CenterAug 5, 2025
        Pharmacokinetic Modelling of Levosimendan in AdultsLevosimendan—Not yet recruitingUniversity Hospital, RouenMay 29, 2025
        LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFLevosimendanPhase 3Active, not recruitingTenax Therapeutics, Inc.Aug 9, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095202, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.